Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Pfizer is adding to its cardiometabolic pipeline with a new, glucagon-like peptide 1 (GLP-1) receptor agonist-focused license agreement, worth up to $1.935 billion
Get what works
Most patients experience shedding 2 to 3 months after starting treatment, with regrowth beginning once weight stabilizes
No additional fees or membership costs Direct from licensed pharmacy Same price, every dose Compounded in the USA Starter program $149/mo $299 total for 2 months Transfer program $224/mo * $449 total for 2 months *Monthly plans are available for $299 per month for those currently taking a GLP-1 medication
Retatrutide is currently in Phase 3 clinical trials under the TRIUMPH program
Lipid peroxidation and its products can affect membrane function and ultimately lead to cell death
US$ 26.65
US$ 20.29
US$ 28.94
US$ 23.13
US$ 28.70
US$ 25.35
